Cosmo Pharmaceuticals N.V. (C43.F)

72.50 -2.00 (-2.68%) As of 11:30AM CEST. Market open.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mauro Severino Ajani	Founder & Executive Chairman	400k	N/A	1955
Mr. Alessandro E. Della Cha LL.M	CEO & Executive Director	1.05M	N/A	1963
Mr. Ngo Dinh Nhan	President of Cosmo Intelligent Medical Devices	N/A	N/A	1979
Mr. Giulio Evangelisti	SVP of Manufacturing, Service and Security (IMD)	N/A	N/A	1970
Mr. Niall Donnelly	Chief Financial Officer	N/A	N/A	1972
Mr. Marco Lecchi	Chief Operating Officer	N/A	N/A	1964
Mr. Davide Malavasi	Qualified Person & Technical Director	N/A	N/A	1973
Mr. Luigi Longo	Chief Scientific Officer	N/A	N/A	1979
Ms. Hazel Winchester	Head of Investor Relations	N/A	N/A	1971
Mr. Biagio Vigano	Chief People Officer	N/A	N/A	1974

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Corporate Governance

Cosmo Pharmaceuticals N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.